Update in lean metabolic dysfunction-associated steatotic liver disease
CONCLUSION: MASLD is a complex disease comprising epigenetic, genetic, and metabolic factors in its pathogenesis. Results vary across populations, gender, and age. Limited data exists on clinical practice guidelines for lean patients. Future studies employing this new nomenclature can contribute to standardizing and generalizing results among lean patients with steatotic liver disease.PMID:38577539 | PMC:PMC10989317 | DOI:10.4254/wjh.v16.i3.452
Source: World Journal of Hepatology - Category: Gastroenterology Authors: Karina Sato-Espinoza Perapa Chotiprasidhi Mariella R Huaman Javier D íaz-Ferrer Source Type: research
More News: Alcoholism | Cardiology | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Gastroenterology | Genetics | Heart | Hypertension | International Medicine & Public Health | Liver | Liver Disease | Metabolic Syndrome | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Study | Urology & Nephrology | WHO